poisar

Stocks · News reference

MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant

Benzinga Newsdesk

Study OverviewMN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and hypertriglyceridemia associated

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MNOV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Yuichi Iwaki, Ph.D.

    MediciNova CEO Provides Shareholder Update

    MediciNova reported topline results from its Phase 2 trial of MN-001 (tipelukast) for nonalcoholic fatty liver disease and hypertriglyceridemia, which did not achieve statistical significance on primary endpoints but showed encouraging signals including significant improvements in HDL cholesterol and early triglyceride reduction. The company also announced completion of patient enrollment in its Phase 2b/3 COMBAT-ALS trial for MN-166 (ibudilast), with topline results expected by year-end.

    MNOV
  2. Benzinga Newsdesk

    MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance

    To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2

    MNOV
  3. Medicinova, Inc.

    MediciNova to Participate in the Maxim Growth Summit

    MediciNova announced that management will participate in the Maxim Growth Summit on October 12-14, 2026, in New York to meet with investors. The company is developing late-stage clinical programs for inflammatory, fibrotic, and neurodegenerative diseases, with lead asset MN-166 (ibudilast) in trials for ALS, DCM, and MS, and MN-001 (tipelukast) being evaluated for IPF and NAFLD.

    MNOV